Ocugen Inc (NASDAQ: OCGN)’s stock price has gone rise by 1.36% in comparison to its previous close of $0.96, however, the company has experienced a -1.43% decrease in its stock price over the last five trading days. globenewswire.com reported 2025-06-23 that PHILADELPHIA and MALVERN, Pa., June 23, 2025 (GLOBE NEWSWIRE) — Carisma Therapeutics Inc. (Nasdaq: CARM) (Carisma) and OrthoCellix, Inc. (OrthoCellix), a wholly-owned subsidiary of Ocugen, Inc. (Nasdaq: OCGN) (Ocugen), a clinical-stage company developing regenerative cell therapies for orthopedic diseases, today jointly announced that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will focus on the development of OrthoCellix’s NeoCart® technology for the treatment of knee articular cartilage defects and plans to initiate a U.S. Food and Drug Administration (FDA)-endorsed Phase 3 clinical trial for NeoCart®.
Is It Worth Investing in Ocugen Inc (NASDAQ: OCGN) Right Now?
OCGN has 36-month beta value of 3.85. Analysts have mixed views on the stock, with 2 analysts rating it as a “buy”, 2 as “overweight”, 0 as “hold”, and 0 as “sell”.
The public float for OCGN is 286.77M, and currently, short sellers hold a 22.73% ratio of that float. The average trading volume of OCGN on July 08, 2025 was 5.60M shares.
OCGN’s Market Performance
The stock of Ocugen Inc (OCGN) has seen a -1.43% decrease in the past week, with a 9.33% rise in the past month, and a 51.87% gain in the past quarter. The volatility ratio for the week is 6.48%, and the volatility levels for the past 30 days are at 9.31% for OCGN.. The simple moving average for the past 20 days is -7.57% for OCGN’s stock, with a 17.00% simple moving average for the past 200 days.
Analysts’ Opinion of OCGN
Many brokerage firms have already submitted their reports for OCGN stocks, with Maxim Group repeating the rating for OCGN by listing it as a “Buy”. The predicted price for OCGN in the upcoming period, according to Maxim Group is $4 based on the research report published on October 15, 2024 of the previous year 2024.
Chardan Capital Markets, on the other hand, stated in their research note that they expect to see OCGN reach a price target of $3.50. The rating they have provided for OCGN stocks is “Buy” according to the report published on March 01st, 2023.
ROTH Capital gave a rating of “Buy” to OCGN, setting the target price at $8 in the report published on June 15th of the previous year.
OCGN Trading at 9.02% from the 50-Day Moving Average
After a stumble in the market that brought OCGN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -50.99% of loss for the given period.
Volatility was left at 9.31%, however, over the last 30 days, the volatility rate increased by 6.48%, as shares surge +1.79% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +35.29% upper at present.
During the last 5 trading sessions, OCGN fell by -1.43%, which changed the moving average for the period of 200-days by -17.09% in comparison to the 20-day moving average, which settled at $1.0494. In addition, Ocugen Inc saw -39.75% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Fernandes Prabhavathi, the Director of Ocugen Inc, purchase 10,000 shares at $0.91 during a trade that took place back on Nov 26 ’24, which means that Fernandes Prabhavathi is holding 10,000 shares at $9,095 based on the most recent closing price.
Stock Fundamentals for OCGN
Current profitability levels for the company are sitting at:
- -12.61% for the present operating margin
- 1.0% for the gross margin
The net margin for Ocugen Inc stands at -12.71%. The total capital return value is set at -1.2%. Equity return is now at value -248.97%, with -98.89% for asset returns.
Based on Ocugen Inc (OCGN), the company’s capital structure generated 0.21 points at debt to capital in total, while cash flow to debt ratio is standing at -12.25. The debt to equity ratio resting at 0.26. The interest coverage ratio of the stock is -62.41.
Currently, EBITDA for the company is -52.79 million with net debt to EBITDA at 0.62. When we switch over and look at the enterprise to sales, we see a ratio of 55.2. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.60.
Conclusion
To put it simply, Ocugen Inc (OCGN) has had a mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
